Want to see CRDF full AI Analyst Report?
CRDF Stock Chart & Stats
$0.83
$0.02(2.30%)
At close: 4:00 PM EDT
$0.83
$0.02(2.30%)
Day’s Range― - ―
52-Week Range$0.76 - $3.31
Previous CloseN/A
Volume462.43K
Average Volume (3M)1.68M
Market Cap
$74.92M
Enterprise Value$54.85
Total Cash (Recent Filing)$34.52M
Total Debt (Recent Filing)$457.00K
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Oct 29, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding77,795,250
10 Day Avg. Volume2,518,065
30 Day Avg. Volume1,675,576
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)4.14
Price to Sales (P/S)316.73
P/FCF Ratio-4.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.01Price Target Upside503.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.68
Revenue Forecast (FY)$244.00K
Bulls Say, Bears Say
Bulls Say
Promising Phase 2 Onvansertib DataInterim Phase 2 results showing a 72% objective response rate and PFS not yet reached establish a clear registrational path and dose selection for Phase 3. Robust, reproducible clinical efficacy in first‑line RAS‑mutated CRC materially strengthens long‑term commercial potential and regulatory trajectory.
Conservative Financial LeverageExtremely low debt reduces solvency and interest burden risks, preserving flexibility to fund development through equity or partnerships. Conservative leverage improves downside resilience for a pre‑commercial biotech, lowering near‑term bankruptcy probability while management pursues clinical milestones.
Shareholder Approval Of Governance And Equity PlanStrong shareholder support for the board, auditor ratification, and expanded equity incentive reserve sustains management continuity and talent incentives. This governance stability and capacity to grant compensation equity help retain key R&D staff and align incentives through multi‑year development programs.
Bears Say
Persistent High Cash BurnSustained negative operating and free cash flow at ~-$37M annually creates a structural funding requirement. Without product revenues, the company must rely on equity raises, partnerships, or debt, increasing dilution risk and potentially constraining strategic choices over the next several quarters.
Minimal Revenue And Sustained LossesVery limited revenue and large recurring operating losses mean the business cannot self‑fund R&D or commercialization. Continued negative profitability erodes equity and reduces financial optionality, making long‑term progress highly dependent on external financing or partner deals.
License And Patent Dispute Over OnvansertibAn active legal dispute and attempted license termination threaten Cardiff’s control of its lead asset and related IP. Litigation could delay trials, block regulatory filings or require renegotiation, introducing material execution risk that could impair the program's registrational and commercial prospects.
Cardiff Oncology News
CRDF FAQ
What was Cardiff Oncology, Inc.’s price range in the past 12 months?
Cardiff Oncology, Inc. lowest stock price was $0.76 and its highest was $3.31 in the past 12 months.
What is Cardiff Oncology, Inc.’s market cap?
Cardiff Oncology, Inc.’s market cap is $74.92M.
When is Cardiff Oncology, Inc.’s upcoming earnings report date?
Cardiff Oncology, Inc.’s upcoming earnings report date is Oct 29, 2026 which is in 74 days.
How were Cardiff Oncology, Inc.’s earnings last quarter?
Cardiff Oncology, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.12 by -$0.02.
Is Cardiff Oncology, Inc. overvalued?
According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued.
Does Cardiff Oncology, Inc. pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
What is Cardiff Oncology, Inc.’s EPS estimate?
Cardiff Oncology, Inc.’s EPS estimate is -0.15.
How many shares outstanding does Cardiff Oncology, Inc. have?
Cardiff Oncology, Inc. has 77,795,250 shares outstanding.
What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?
Cardiff Oncology, Inc. reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.12. Following the earnings report the stock price went down -5.714%.
Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?
Currently, no hedge funds are holding shares in CRDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiff Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.01 (503.61% Upside)
$5.01 (503.61% Upside)
Blogger Sentiment
Bullish
CRDF Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 10.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-50.71%
Trailing 12-Months
Company Description
Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
CRDF Stock 12 Month Forecast
Average Price Target
$5.01
▲(503.61% Upside)
Technical Analysis
Oncolytics Biotech
―
―
Avalo Therapeutics
―
Greenwich LifeSciences
―
Molecular Partners
―
Pyxis Oncology
―
Ownership Overview
2.89% Insiders
6.97% Mutual Funds
9.33% Other Institutional Investors
76.88% Public Companies and
Individual Investors